|Day's Range||27.19 - 27.52|
|52 Week Range||19.67 - 27.52|
|PE Ratio (TTM)||87.56|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||29.41|
Let’s look at Wall Street analysts’ recommendations and target prices for Boston Scientific (BSX) over the next 12 months.
On May 9, 2017, Boston Scientific (BSX) announced the FDA approval of its Resonate family of products, including its ICD and CRT-D systems.
Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.